Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

50 Milk Street, 10th Floor, Boston, United States

WallStreetWoof Jun. 5 at 7:27 PM

$LAB I expect LAB to bounce to $1.50 soon...

0 · Reply

WallStreetWoof Jun. 4 at 5:07 PM

$LAB I found my buck and a quarter - quarterstaff....

0 · Reply

OriginalTradeonrumor Jun. 4 at 3:33 PM

$LAB everyone enjoying the ‘20’s!?? Those that trade with me we started this in the 80’s/low .90’s ~2months ago…now look at us …all grown up! Still have some gaining to do!! Then We have the inevitable announcement regarding use of their few hundred million If its decent we get into the 2’s in a blink of an eye But We need to be in the ~1.50’s to launch from there …and that’s what I believe is going to happen Let’s see what happens!

0 · Reply

WallStreetWoof Jun. 2 at 12:28 PM

$LAB Daffy let me know my quarterstaff is actually a 1.25 staff...inflation.

0 · Reply

Lussu1986 May. 29 at 9:21 PM

$LAB Last trade was 3.48mm shares and overall volume was highest I have seen in a while. Nice to see some buyers show up!

0 · Reply

VJLer May. 29 at 9:00 PM

$LAB The company filed an 8K on May 28th, 2026 that announced the approval of the 2026 change of control plan. The text is just a Para or so but references: Under the 2026 Severance Plan, if the executive’s employment is terminated outside of the period beginning three months before a Change of Control (as defined in the 2026 Severance Plan) and ending 12 months after a Change of Control (such period, the “Change of Control Period”) for a reason other than Cause (as defined in the 2026 Severance Plan) or the executive’s death or Disability (as defined in the 2026 Severance Plan), then, subject to the severance conditions provided in the 2026 Severance Plan, the executive will be entitled to receive the following severance benefits . . . Is this filing just a coincidence? Or is there something to it?

0 · Reply

WallStreetWoof May. 29 at 7:21 PM

$LAB Book value is 1.44 per Y! and for the last month, LAB has been closing strong. No reason the trend should not continue to 1.5, where the share price was in January, imho.

0 · Reply

OriginalTradeonrumor May. 29 at 6:39 PM

$LAB 1.18 HIGH so far today …if you follow me you should not be surprised as I said we’d be here much sooner than it took to hit 1 and 1.10….i think keep above 1.20 we’ll need more volume so perhaps a PR or juicy rumor …other than that we probably don’t get past or deep into the 1.20’s for any length of time. Def not complaining as I believe we will hit 1.50 eventually this summer and from there it will all depend on actual results /news. Millions of shares have been purchased over the last few months and a very significant % of them by activist tutes who aren’t looking to make 10% on their money lol If$LAB stays on track with profitability and they invest their ~few hundred million cash efficiently …getting deep into $2 territory will be a heartbeat away. Let’s see what happens!

0 · Reply

TI7812 May. 28 at 8:00 PM

$LAB another Mak Capital holding. about $1.35 to $1.41/cash per share (no real debt) Inflection year 2026?

0 · Reply

OriginalTradeonrumor May. 28 at 7:35 PM

$LAB as I said 😁

0 · Reply

Standard BioTools Reports First Quarter 2026 Financial Results

May 5, 2026, 4:00 PM EDT - 4 weeks ago

Standard BioTools Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 4 weeks ago

Standard BioTools Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Standard BioTools Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Standard BioTools Proxy statement: Proxy filing

2026-02-24T21:17:26.000Z - 3 months ago

Standard BioTools reports Q4 EPS 5c vs (9c) last year

2026-02-24T21:16:44.000Z - 3 months ago

Standard BioTools sees FY26 revenue $80M-$85M, consensus $79.73M

Feb 24, 2026, 4:10 PM EST - 3 months ago

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 4:00 PM EST - 3 months ago

Standard BioTools Annual report: Q4 2025

Feb 24, 2026, 4:00 PM EST - 3 months ago

Standard BioTools Earnings release: Q4 2025

Feb 10, 2026, 7:00 AM EST - 4 months ago

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

2026-01-30T14:16:09.000Z - 4 months ago

Standard BioTools completes sale of SomaLogic to Illumina

ILMN

Jan 30, 2026, 9:09 AM EST - 4 months ago

Standard BioTools Completes Sale of SomaLogic to Illumina

2026-01-08T12:05:40.000Z - 5 months ago

Standard BioTools sees Q4 revenue from cont. ops. $24M, consensus $18.5M

Jan 8, 2026, 7:00 AM EST - 5 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Nov 19, 2025, 11:30 AM EST - 7 months ago

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 7 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

2025-11-05T13:50:39.000Z - 7 months ago

Standard BioTools price target lowered to $1.35 from $1.55 at TD Cowen

Nov 4, 2025, 4:05 PM EST - 7 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:00 PM EST - 7 months ago

Standard BioTools Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 7 months ago

Standard BioTools Earnings release: Q3 2025

Oct 21, 2025, 7:00 AM EDT - 8 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 9 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

2025-08-13T10:05:55.000Z - 10 months ago

Standard BioTools downgraded to Hold from Buy at TD Cowen

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Standard BioTools Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Standard BioTools Earnings release: Q2 2025

2025-08-11T20:16:09.000Z - 10 months ago

Standard BioTools reports Q2 EPS (9c), consensus (4c)

2025-08-11T20:15:49.000Z - 10 months ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $169.13M

Aug 11, 2025, 4:01 PM EDT - 10 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

2025-08-06T11:30:45.000Z - 10 months ago

Standard BioTools, Precision Health, Singapore launch proteomic collaboration

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 11 months ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

2025-06-23T17:12:37.000Z - 1 year ago

Standard BioTools to sell SomaLogic to Illumina for $350M upfront payment

ILMN

2025-06-23T17:10:18.000Z - 1 year ago

Illumina to acquire SomaLogic for $350M in cash

ILMN

Jun 23, 2025, 7:13 AM EDT - 1 year ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 1 year ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

2025-05-30T11:15:44.000Z - 1 year ago

Standard BioTools to host inaugural ‘Proteomics Roundtable’ series

May 30, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Slides: Q1 2025

2025-05-06T20:16:39.000Z - 1 year ago

Standard BioTools reports Q1 EPS (7c), consensus (4c)

May 6, 2025, 4:01 PM EDT - 1 year ago

Standard BioTools Reports First Quarter 2025 Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Standard BioTools Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Standard BioTools Proxy statement: Proxy Filing

2025-04-24T11:16:19.000Z - 1 year ago

Standard BioTools announces new product innovations at AACR 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Transcript: KeyBanc Annual Health Care Forum 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Standard BioTools Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 4:01 PM EST - 1 year ago

Standard BioTools to Participate in Upcoming Investor Conferences

2025-02-27T09:40:45.000Z - 1 year ago

Standard BioTools downgraded to Sector Weight from Overweight at KeyBanc

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Slides: Q4 2024

2025-02-26T21:27:29.000Z - 1 year ago

Standard BioTools reports Q4 EPS (9c), consensus (3c)

2025-02-26T21:26:38.000Z - 1 year ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $186.93M

Feb 26, 2025, 4:01 PM EST - 1 year ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Standard BioTools Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Standard BioTools Slides: FY 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 19, 2024, 3:30 AM EST - 1 year ago

Standard BioTools Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 3:30 AM EST - 1 year ago

Standard BioTools Slides: FY 2024

Nov 12, 2024, 4:15 PM EST - 1 year ago

Standard BioTools Transcript: UBS Global Healthcare Conference 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Quarterly report: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings release: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Slides: Q3 2024

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Standard BioTools Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Standard BioTools Transcript: UBS Genomic Medicine Summit

Aug 13, 2024, 9:00 AM EDT - 1 year ago

Standard BioTools Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Quarterly report: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings release: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Slides: Q2 2024

Jul 31, 2024, 4:02 PM EDT - 2 years ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jun 5, 2024, 2:30 PM EDT - 2 years ago

Standard BioTools Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 28, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 21, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Proxy statement: Proxy Filing

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings release: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Slides: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 19, 2024, 10:30 AM EDT - 2 years ago

Standard BioTools Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 18, 2024, 8:12 AM EDT - 2 years ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Mar 6, 2024, 1:30 PM EST - 2 years ago

Standard BioTools Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Slides: Q4 2023

Feb 28, 2024, 4:01 PM EST - 2 years ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 2 years ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Feb 2, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 19, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 19, 2024, 7:00 AM EST - 2 years ago

Standard BioTools Registration statement: Registration Filing

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 9:44 PM EST - 2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Dec 31, 2023, 2:10 PM EST - 2 years ago

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Dec 29, 2023, 7:10 PM EST - 2 years ago

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Dec 29, 2023, 5:04 PM EST - 2 years ago

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

Dec 28, 2023, 4:16 PM EST - 2 years ago

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

Dec 22, 2023, 8:11 PM EST - 2 years ago

Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools

Dec 22, 2023, 8:00 PM EST - 2 years ago

Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

WallStreetWoof Jun. 5 at 7:27 PM

$LAB I expect LAB to bounce to $1.50 soon...

0 · Reply

WallStreetWoof Jun. 4 at 5:07 PM

$LAB I found my buck and a quarter - quarterstaff....

0 · Reply

OriginalTradeonrumor Jun. 4 at 3:33 PM

0 · Reply

WallStreetWoof Jun. 2 at 12:28 PM

$LAB Daffy let me know my quarterstaff is actually a 1.25 staff...inflation.

0 · Reply

Lussu1986 May. 29 at 9:21 PM

$LAB Last trade was 3.48mm shares and overall volume was highest I have seen in a while. Nice to see some buyers show up!

0 · Reply

VJLer May. 29 at 9:00 PM

0 · Reply

WallStreetWoof May. 29 at 7:21 PM

$LAB Book value is 1.44 per Y! and for the last month, LAB has been closing strong. No reason the trend should not continue to 1.5, where the share price was in January, imho.

0 · Reply

OriginalTradeonrumor May. 29 at 6:39 PM

0 · Reply

TI7812 May. 28 at 8:00 PM

$LAB another Mak Capital holding. about $1.35 to $1.41/cash per share (no real debt) Inflection year 2026?

0 · Reply

OriginalTradeonrumor May. 28 at 7:35 PM

$LAB as I said 😁

0 · Reply

OriginalTradeonrumor May. 28 at 4:26 PM

$LAB congrats all! More to come !!!

1 · Reply

OriginalTradeonrumor May. 28 at 2:14 PM

$LAB another run at 1.10 today …only a matter of time ( short time!)😎

1 · Reply

OriginalTradeonrumor May. 27 at 10:22 PM

$LAB I gobbled more at 1.03 and 1.04…nice spike at the end!

0 · Reply

OriginalTradeonrumor May. 26 at 8:10 PM

$LAB very close to 1.10! Once we break that 1.15-1.20 comes A LOT QUICKER than 1-1.10!!!!!

1 · Reply

OriginalTradeonrumor May. 26 at 2:46 PM

$LAB trading solid above $1 now…should be sniffing at 1.10 soon 🥳

0 · Reply

Wisenheimer May. 26 at 2:05 PM

$LAB removed from the Russell

0 · Reply

MoneyTree82 May. 22 at 3:18 PM

$LAB we need someone to buy up all the 1.03’s And then all the $1.04s And so on … let’s bump this over $1.10 before weekend Undervalued! $NDAQ

0 · Reply

MoneyTree82 May. 22 at 2:46 PM

$LAB Volume is going slow this morning! Next leg to $1.10-1.12?🤔

0 · Reply

MoneyTree82 May. 21 at 1:56 PM

$LAB little morning shake! Would love to see trend continuation! Undervalued!

0 · Reply

WallStreetWoof May. 21 at 1:38 PM

$LAB Glad yesterday broke above $1.03. Lets shoot for $1.10 close for today.... Book Value is $1.44 so a long way to go just to be in the vicinity of a fair valuation....imho

0 · Reply

beckphan08 May. 20 at 11:16 PM

$LAB hmm

0 · Reply

OriginalTradeonrumor May. 20 at 8:18 PM

$LAB great day today …hold the line at 1.00 for 9 more trading days and we back compliant!!!

0 · Reply

Market Cap	448.92M
Revenue (ttm)	85.33M
Net Income (ttm)	-74.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-87.78%
Debt to Equity Ratio	0.00

Volume	3,499,500
Avg Vol	2,632,988
Day's Range	N/A - N/A
Shares Out	390.37M
Stochastic %K	48%
Beta	1.39
Analysts	Sell
Price Target	$1.55